U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07497620) titled 'Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP' on March 23.

Brief Summary: The purpose of this study is to valuate the clinical efficacy of Bimzelx therapy in adults with Pityriasis Rubra Pilaris.

Study Start Date: July 01, 2026

Study Type: INTERVENTIONAL

Condition: Pityriasis Rubra Pilaris

Intervention: DRUG: Bimekizumab

Subjects will receive subcutaneous injection of 320 mg at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter for 24 weeks.

For patients weighing >= 120 kg, 320 mg every 4 weeks after Week 16, for 24 weeks.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Mayo Clinic

Information provide...